The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen

Chien-Yu Lu; Hsiang-Lin Tsai; Jaw-Yuan Wang

首页> 外文期刊>Biomarkers and genomic medicine. >The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen

【24h】

The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen

机译：UGT1A1基因多态性用于伊立替康剂量调整的FOLFIRI加贝伐单抗一线方案治疗转移性结直肠癌患者的剂量

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Biomarkers and genomic medicine.》 |2013年第3期|共2页
作者
Chien-Yu Lu; Hsiang-Lin Tsai; Jaw-Yuan Wang;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF -Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI [J] . Yi-Chien Hsieh, Tsung-Kun Chang, Wei-Chih Su, Journal of oncology . 2021,第a期

机译：用一线Bevacizumab和Folfiri治疗BRAF级化转移性结直肠癌患者的伊替康剂量升级的UGT1A1多态性
2. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial [J] . Yung-Sung Yeh, Hsiang-Lin Tsai, Ching-Wen Huang, Trials . 2016,第1期

机译：UGT1A1启动子多态性用于贝伐单抗联合FOLFIRI作为一线治疗的转移性结直肠癌患者中伊立替康剂量递增的前瞻性研究：一项随机对照试验的研究方案
3. Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting [J] . Chien-Yu Lu, Ching-Wen Huang, I-Chen Wu, Translational Oncology . 2015,第6期

机译：贝伐单抗联合FOLFIRI治疗一线治疗中 UGT1A1 启动子多态性对伊立替康剂量递增的转移性结直肠癌患者的临床意义
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI [O] . Yi-Chien Hsieh, Tsung-Kun Chang, Wei-Chih Su, 2021

机译：用一线Bevacizumab和Folfiri治疗Braf-突变转移性结肠直肠癌患者的伊替康剂量升级的UGT1A1多态性
7. The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen [O] . Lu Chien-Yu, Tsai Hsiang-Lin, Wang Jaw-Yuan 2013

机译：UGT1A1基因多态性用于伊立替康剂量调整的FOLFIRI加贝伐单抗一线方案治疗转移性结直肠癌患者的剂量

The genotyping of UGT1A1 polymorphism for the dose adjustment of irinotecan in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab as the first-line regimen

著录项

相似文献

相关主题

期刊订阅